In yesterday’s Wall Street session, BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) shares traded at $85.00, down -1.94% from the previous session.
26 analysts cover BioMarin Pharmaceutical Inc. (NASDAQ:BMRN), according to research data. The consensus rating among analysts is ‘Overweight’. As we calculate the median target price by taking the range between a high of $200.00 and a low of $73.00, we find $119.00. Given the previous closing price of $86.68, this indicates a potential upside of 37.29 percent. BMRN stock price is now -8.75% away from the 50-day moving average and -11.87% away from the 200-day moving average. The market capitalization of the company currently stands at $16.55B.
The stock has received a hold rating from 9 analysts and a buy rating from 14. Brokers who have rated the stock have averaged $119.22 as their price target over the next twelve months.
In other news, BIENAIME JEAN JACQUES, Chief Executive Officer sold 30,000 shares of the company’s stock on May 11. The stock was sold for $2,840,226 at an average price of $94.67. Upon completion of the transaction, the Chief Executive Officer now directly owns 426,213 shares in the company, valued at $36.23 million. An SEC document containing details of the transaction can be found on the SEC’s website. On May 10, Chief Executive Officer BIENAIME JEAN JACQUES sold 30,000 shares of the business’s stock. A total of $2,845,397 was realized by selling the stock at an average price of $94.85. This leaves the insider owning 426,213 shares of the company worth $36.23 million. Insiders disposed of 590,921 shares of company stock worth roughly $50.23 million over the past 1 year. A total of 0.30% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in BMRN stock. A new stake in BioMarin Pharmaceutical Inc. shares was purchased by REDMILE GROUP, LLC during the first quarter worth $28,788,000. HHLR ADVISORS, LTD. invested $26,514,000 in shares of BMRN during the first quarter. In the first quarter, AVIDITY PARTNERS MANAGEMENT LP acquired a new stake in BioMarin Pharmaceutical Inc. valued at approximately $25,816,000. THORNBURG INVESTMENT MANAGEMENT INC acquired a new stake in BMRN for approximately $13,036,000. LOGOS GLOBAL MANAGEMENT LP purchased a new stake in BMRN valued at around $12,884,000 in the second quarter. In total, there are 883 active investors with 100.41% ownership of the company’s stock.
On Monday morning BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) stock kicked off with the opening price of $86.21. During the past 12 months, BioMarin Pharmaceutical Inc. has had a low of $80.53 and a high of $117.77. As of last week, the company has a debt-to-equity ratio of 0.00, a current ratio of 4.80, and a quick ratio of 3.20. According to the stock market information, the enterprise value for the company is $16.21B, which is based on a 228.49 price-to-earnings ratio, a 3.94 price-to-earnings-growth ratio, and a beta of 0.37. The fifty day moving average price for BMRN is $92.93 and a two-hundred day moving average price translates $96.45 for the stock.
The latest earnings results from BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) was released for Mar, 2023. According to the Biotechnology Company, earnings per share came in at $0.27, beating analysts’ expectations of $0.18 by 0.09. This compares to $0.62 EPS in the same period last year. The net profit margin was 3.30% and return on equity was 1.60% for BMRN. The company reported revenue of $596.41 million for the quarter, compared to $519.36 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 14.84 percent. For the current quarter, analysts expect BMRN to generate $600.43M in revenue.
BioMarin Pharmaceutical Inc.(BMRN) Company Profile
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. The company’s commercial products also comprise Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme, which is delivered through subcutaneous injection to reduce blood Phe concentrations; Brineura, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; Voxzogo, a once daily injection analog of c-type natriuretic peptide for the treatment of achondroplasia; and Aldurazyme, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase. In addition, it develops Roctavian, an adeno associated virus vector, for the treatment of patients with severe hemophilia A; BMN 331, an AAV5 mediated gene therapy, which is in Phase 1/2 clinical trial for people living with Hereditary Angioedema (HAE); and BMN 255 that is in Phase 1/2 clinical trial for treating primary hyperoxaluria. The company serves specialty pharmacies, hospitals, and non-U.S. government agencies, as well as distributors and pharmaceutical wholesalers in the United States, Europe, Latin America, and internationally. BioMarin Pharmaceutical Inc. has license and collaboration agreements with Sarepta Therapeutics, Ares Trading S.A., Catalyst Pharmaceutical Partners, Inc., and Asubio Pharma Co., Ltd. The company was incorporated in 1996 and is headquartered in San Rafael, California.
